Advertisement

Buildout and integration of an automated high-throughput CLIA laboratory for SARS-CoV-2 testing on a large urban campus

Open AccessPublished:June 16, 2022DOI:https://doi.org/10.1016/j.slast.2022.06.003

      Abstract

      In 2019, the first cases of SARS-CoV-2 were detected in Wuhan, China, and by early 2020 the first cases were identified in the United States. SARS-CoV-2 infections increased in the US causing many states to implement stay-at-home orders and additional safety precautions to mitigate potential outbreaks. As policies changed throughout the pandemic and restrictions lifted, there was an increase in demand for COVID-19 testing which was costly, difficult to obtain, or had long turn-around times. Some academic institutions, including Boston University (BU), created an on-campus COVID-19 screening protocol as part of a plan for the safe return of students, faculty, and staff to campus with the option for in-person classes. At BU, we put together an automated high-throughput clinical testing laboratory with the capacity to run 45,000 individual tests weekly by Fall of 2020, with a purpose-built clinical testing laboratory, a multiplexed reverse transcription PCR (RT-qPCR) test, robotic instrumentation, and trained staff. There were many challenges including supply chain issues for personal protective equipment and testing materials in addition to equipment that were in high demand. The BU Clinical Testing Laboratory (CTL) was operational at the start of Fall 2020 and performed over 1 million SARS-CoV-2 PCR tests during the 2020-2021 academic year.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to SLAS Technology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Astuti I.
        • Ysrafil
        Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.
        Diabetes Metab Syndr. 2020; 14: 407
        • Huang C.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
        Lancet North Am Ed. 2020; 395: 497-506
      1. Pneumonia of unknown cause – China. 2022;
        • Holshue M.L.
        • et al.
        First Case of 2019 Novel Coronavirus in the United States.
        N Engl J Med. 2020; 382: 929-936
        • Cucinotta D.
        • Vanelli M.
        WHO declares COVID-19 a pandemic.
        Acta Biomedica. 2020; 91: 157-160
      2. Organization, W. H.Laboratory testing strategy recommendations for COVID-19: interim guidance, 21 March 2020. 6 p. (2020).

        • Hamer D.H.
        • et al.
        Assessment of a COVID-19 Control Plan on an Urban University Campus During a Second Wave of the Pandemic.
        JAMA Netw Open. 2021; 4e2116425
        • Amen A.M.
        • et al.
        Blueprint for a pop-up SARS-CoV-2 testing lab.
        Nat Biotechnol. 2020; 38: 791-797
        • Aitken J.
        • et al.
        Scalable and robust SARS-CoV-2 testing in an academic center.
        Nat Biotechnol. 2020; 38: 927-931
        • Vanuytsel K.
        • et al.
        Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital.
        Med N Y N. 2020; 1: 152
        • BMC-CReM
        BMC-CReM COVID-19 Test.
        Two-Step Singleplex and One-Step Singleplex EUA Summary. 2022;
        • Giadone R.M.
        • et al.
        qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples.
        STAR Protoc. 2020; 1100102
      3. Commissioner, O. of the. Emergency Use Authorization. FDAhttps://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization (2021).

      4. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) - Guidance for Developers and Food and Drug Administration Staff. 2022;
      5. Code of Federal Regulations 42 CFR §. 2022; 493
      6. CLIA Regulations and Federal Register Documents.
        CMS. 2022;
        • Chowdhury P.
        • Paul S.K.
        • Kaisar S.
        • Moktadir M.A.
        COVID-19 pandemic related supply chain studies: A systematic review.
        Transp Res Part E Logist Transp Rev. 2021; 148102271
        • CDC. Labs
        Centers for Disease Control and Prevention. 2020;
        • Lu X.
        • et al.
        US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome Coronavirus 2.
        Emerg Infect Dis. 2020; 26: 1654-1665
        • FDA
        TaqPath COVID-19 Combo Kit - Letter of Authorization. 2020;
        • CDC
        Overview of Testing for SARS-CoV-2 (Covid-19.
        Centers for Disease Control and Prevention. 2020;
      7. User Guide: MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit. 2022 https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%-2Fmanuals-%2FMAN0024756_MVPII_RUO_UG.pdf&title=VXNlciBHdWlkZTogTWFnTUFYIFZ-pcmFsL1BhdGhvZ2VuIElJIE51Y2xlaWMgQWNpZCBJc29sYXRpb24gS2l0.

        • Coffee E.M.
        • Tolan D.R
        Mutations in the Promoter Region of the Aldolase B Gene that cause Hereditary Fructose Intolerance.
        J Inherit Metab Dis. 2010; 33: 715-725
        • FDA
        In Vitro Diagnostics EUAs.
        FDA Molecular Diagnostic Template for Laboratories. 2022;
      8. Pooled Sample Testing and Screening Testing for COVID-19.
        FDA. 2022;
        • Christie A.
        • et al.
        Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021.
        Morb Mortal Wkly Rep. 2021; 70: 858
        • Davidi D.
        • et al.
        Amplicon residues in research laboratories masquerade as COVID-19 in surveillance tests.
        Cell Rep Methods. 2021; 1100005
        • Landaverde L.
        • et al.
        Comparison of BinaxNOWTM and SARS-CoV-2 qRT-PCR detection of the Omicron Variant from Matched Anterior Nares Swabs. 2022; (2022.01.31.22270206)https://doi.org/10.1101/2022.01.31.22270206
        • Petros B.A.
        • et al.
        Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations. 2022; (2022.01.27.22269787)https://doi.org/10.1101/2022.01.27.22269787
        • Landsberg H.E.
        • et al.
        Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster.
        Int J Infect Dis. 2022; 114: 62-64
        • Kuhfeldt K.
        • et al.
        Minimal SARS-CoV-2 classroom transmission at a large urban university experiencing repeated into campus introduction. 2022; (2022.03.16.22271983)https://doi.org/10.1101/2022.03.16.22271983
        • Liu A.B.
        • et al.
        Association of COVID-19 Quarantine Duration and Postquarantine Transmission Risk in 4 University Cohorts.
        JAMA Netw Open. 2022; 5e220088
        • Bouton T.C.
        • et al.
        Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study.
        medRxiv. 2022; (2022.04.04.22273429)https://doi.org/10.1101/2022.04.04.22273429